Drug interactions
Insulin aspart + Metformin-pioglitazone
Severity: Major
Insulin aspart and Metformin-pioglitazone: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pioglitazone combined with insulin increases the risk of fluid retention, edema and heart failure, and glucose-lowering effects are additive so hypoglycemia can occur. Metformin adds to the glucose-lowering effect.
What this interaction means in plain words
Insulin aspart and Metformin-pioglitazone can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Insulin aspart belongs to Endocrine; Metformin-pioglitazone belongs to Endocrine.
Why it happens
Additive glucose lowering, with insulin and PPAR-gamma agonism both promoting sodium and fluid retention.
What to do
Monitor weight, edema and signs of heart failure, and reduce the insulin dose if hypoglycemia occurs. Avoid in patients with symptomatic heart failure.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Insulin aspart and Metformin-pioglitazone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Metformin-pioglitazone
Other interactions of Insulin aspart
Frequently asked questions
Can I take Insulin aspart with Metformin-pioglitazone?
MediHelp rates the interaction as major. Insulin aspart and Metformin-pioglitazone can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pioglitazone combined with insulin increases the risk of fluid retention, edema and heart failure, and glucose-lowering effects are additive so hypoglycemia can occur. Metformin adds to the glucose-lowering effect.
How serious is the interaction between Insulin aspart and Metformin-pioglitazone?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor weight, edema and signs of heart failure, and reduce the insulin dose if hypoglycemia occurs. Avoid in patients with symptomatic heart failure.
What other medicines interact with Metformin-pioglitazone?
MediHelp also lists interactions of Metformin-pioglitazone with, for example, Contrast media, Diatrizoate meglumine / diatrizoate, Diatrizoate. The full list is on the Metformin-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
